The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL				
OMB Number:	3235- 0076			
Estimated burden	average			
hours per response:	4.00			

1. Issuer's Identity

	Durtan		
CIK (Filer ID Numbe	er) Previous Names	None	Entity Type
<u>0001169245</u>	Phase Biosci	ences Inc	X Corporation
Name of Issuer	DT BIOSCII	ENCES INC	Limited Partnership
PhaseBio Pharmaceuticals Inc			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organiza	ition		Business Trust
DELAWARE	0rganization		Other (Specify)
Year of Incorporation	I/Organization		
X Over Five Years Ago	ifre Voor)		
Within Last Five Years (Spec Yet to Be Formed	city year)		
fet to be Formed			
2. Principal Place of Business an	nd Contact Information		
Name of I	ssuer		
PhaseBio Pharmaceuticals Inc			
Street Add	lress 1	St	reet Address 2
One Great Valley Parkway		Suite 30	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Malvern PI	ENNSYLVANIA	19355	610-981-6500
3. Related Persons			
Last Name	Firs	t Name	Middle Name
Mow	Jonathan		
Street Address 1	Street	Address 2	
1 Great Valley Parkway	Suite 30		
City	State/Prov	vince/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	A 193	55
Relationship: X Executive Off	icer X Director Promot	er	
Clarification of Response (if Ne	cessary):		
Last Name	Firs	t Name	Middle Name
Sussman	Joel		
Street Address 1		Address 2	
1 Great Valley Parkway	Suite 30		
City	State/Prov	vince/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	A 193	55
Relationship: X Executive Off	icer Director Promote	Pr	

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Chilkoti	Ashutosh	
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executive Office	er X Director Promoter	
Clarification of Response (if Nece	essary):	
Last Name	First Name	Middle Name
Thorp	Clay	
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executive Office	er X Director Promoter	
Clarification of Response (if Nece	essary):	
Last Name	First Name	Middle Name
Xavier	Asish	К.
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executive Office	er X Director Promoter	
Clarification of Response (if Nece		
Last Name	First Name	Middle Name
Fish	Guy	
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executive Office	er X Director Promoter	
Clarification of Response (if Nece	essary):	
Last Name	First Name	Middle Name
Barrett	James	
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executive Office	er X Director Promoter	
Clarification of Response (if Nece	essary):	
Last Name	First Name	Middle Name
Klein	Justin	
Street Address 1	Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

L	ast Name	First Name		Middle Name
Ingram		Robert		
Stre	et Address 1	Street Address 2		
1 Great Valley	Parkway	Suite 30		
	City	State/Province/Country		ZIP/PostalCode
Malvern		PENNSYLVANIA	19355	
Relationship:	Executive Officer	X Director Promoter		
Clarification of	Desponse (if Nesse			

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Gutch	Michael	
Street Address	s 1 Street Address 2	
1 Great Valley Parkway	Suite 30	
City	State/Province/Country	ZIP/PostalCode
Malvern	PENNSYLVANIA	19355
Relationship: Executiv	e Officer X Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financia Commercial Bank Insurance		Health Care X Biotechnology Health Insurance Hospitals & Physicians	Retailing Restaurants Technology Computers
Investing Investment Bankin	0	Pharmaceuticals	Telecommunications
Pooled Investmen Is the issuer regist	ered as	Other Health Care Manufacturing	Other Technology Travel
an investment con the Investment Cc Act of 1940?		Real Estate Commercial	Airlines & Airports Lodging & Conventions
Yes	No	Construction	Tourism & Travel Services
Other Banking &	Financial Services	REITS & Finance	Other Travel
Business Services		Residential	Other
Energy Coal Mining		Other Real Estate	

5. Issuer Size

Oil & Gas

Other Energy

Electric Utilities

Energy Conservation Environmental Services

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000

\$5,000,001 - \$25,000,000	\$25,000,001 - \$5	50,000,000	
\$25,000,001 - \$100,000,000	\$50,000,001 - \$2	100,000,000	
Over \$100,000,000	Over \$100,000,0	000	
X Decline to Disclose	Decline to Discl		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion(s) Clain	ned (select all that	apply)	
	Investment	Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)	(1) Section 3(c)(9)	
Rule 504 (b)(1)(i)	Section 3(c)		
Rule 504 (b)(1)(ii)	Section 3(c)		
Rule 504 (b)(1)(iii) Rule 505			
X Rule 505 X Rule 506(b)	Section 3(c)		
Rule 506(c)	Section 3(c)	(5) Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)	(6) Section 3(c)(14)	
	Section 3(c)	(7)	
7. Type of Filing			
New Notice Date of First Sale 2015-02-26 X Amendment	First Sale Yet to	Occur	
8. Duration of Offering			
Does the Issuer intend this offering to last more	e than one year? Σ	X Yes No	
9. Type(s) of Securities Offered (select all that a	apply)		
X Equity		Pooled Investment Fund Intere	sts
Debt		Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire A	Another Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of O Other Right to Acquire Security	ption, Warrant or	X Other (describe)	
Other Right to Acquire Security		Offer and sale of Series C Preferr	ed Stock, and the underlying
		shares of Common Stock issuable	
10. Business Combination Transaction			
Is this offering being made in connection with a merger, acquisition or exchange offer?	a business combina	ation transaction, such as Yes 2	X No
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outsic	le investor \$0 USE)	
12. Sales Compensation			
Recipient	Recip	ient CRD Number X None	
(Associated) Broker or Dealer X None	(Asso	ciated) Broker or Dealer CRD Nu	ımber X None
Street Address 1		Street Address 2	
City	State/	Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply)	All States For	eign/non-US	

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount\$42,000,000 USD orIndefiniteTotal Amount Sold\$21,000,000 USDTotal Remaining to be Sold\$21,000,000 USD orIndefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$900,000 USD X Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

9		

Issuer	Signature	Name of Signer	Title	Date
PhaseBio Pharmaceuticals Inc	/s/ Joel Sussman	Joel Sussman	Chief Financial Officer	2015-07-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.